Nixon Peabody LLP

  • People
  • Capabilities
  • Insights
  • About

Trending Topics

    • People
    • Capabilities
    • Insights
    • About
    • Locations
    • Events
    • Careers
    • Alumni

    Practices

    View All

    • Affordable Housing
    • Community Development Finance
    • Corporate & Finance
    • Cybersecurity & Privacy
    • Environmental
    • Franchising & Distribution
    • Government Investigations & White Collar Defense
    • Healthcare
    • Intellectual Property
    • International Services
    • Labor & Employment
    • Litigation
    • Private Wealth & Advisory
    • Project Finance
    • Public Finance
    • Real Estate
    • Regulatory & Government Relations

    Industries

    View All

    • Cannabis
    • Consumer
    • Energy
    • Entertainment
    • Financial Services
    • Healthcare
    • Higher Education
    • Infrastructure
    • Manufacturing
    • Non Profit
    • Real Estate
    • Technology

    Value-Added Services

    View All

    • Alternative Fee Arrangements

      Developing innovative pricing structures and alternative fee agreement models that deliver additional value for our clients.

    • Continuing Education

      Advancing professional knowledge and offering credits for attorneys, staff and other professionals.

    • Crisis Advisory

      Helping clients respond correctly when a crisis occurs.

    • DEI Strategic Services

      Providing our clients with legal, strategic, and practical advice to make transformational changes in their organizations.

    • eDiscovery

      Leveraging law and technology to deliver sound solutions.

    • Global Services

      Delivering seamless service through partnerships across the globe.

    • Innovation

      Leveraging leading-edge technology to guide change and create seamless, collaborative experiences for clients and attorneys.

    • IPED

      Industry-leading conferences focused on affordable housing, tax credits, and more.

    • Legal Project Management

      Providing actionable information to support strategic decision-making.

    • Legally Green

      Teaming with clients to advance sustainable projects, mitigate the effects of climate change, and protect our planet.

    • Nixon Peabody Trust Company

      Offering a range of investment management and fiduciary services.

    • NP Capital Connector

      Bringing together companies and investors for tomorrow’s new deals.

    • NP Second Opinion

      Offering fresh insights on cases that are delayed, over budget, or off-target from the desired resolution.

    • NP Trial

      Courtroom-ready lawyers who can resolve disputes early on clients’ terms or prevail at trial before a judge or jury.

    • Social Impact

      Creating positive impact in our communities through increasing equity, access, and opportunity.

    1. Home
    2. Insights
    3. Alerts
    4. Personalized treatment patenting in light of Vanda v. West-WardAlerts

    Alert / Intellectual Property Alert

    Personalized treatment patenting in light of Vanda v. West-Ward

    March 24, 2020

    Share

    By Ravinderjit Braich, Ph.D.

    Supreme Court denying certiorari in patent eligibility case could signify good news for patentees and applicants.

    Recently, the Supreme Court denied several petitions for certiorari in a number of patent eligibility subject matter cases, including diagnostic and treatment methods, from the Federal Circuit. While the denials in these cases do not resolve the uncertainty created by the Alice/Mayo framework,[1] the denial in the Hikma Pharmaceuticals USA Inc. v. Vanda Pharmaceuticals Inc., No. 18-817 (Jan. 13, 2020) case may be positive news for patentees and applicants. By denying Hikma’s petition for certiorari in Vanda v. West-Ward,[2] the Supreme Court indirectly endorsed the patent eligibility of at least some method-of-treatment claims that rely on an underlying natural law.

    Hikma, previously West-Ward Pharmaceuticals, Inc., petitioned for certiorari from the Federal Circuit’s 2018 decision in Vanda in which the Federal Circuit decided that method-of-treatment claims that are directed to particular methods of treatment are patent-eligible even if they rely on an underlying natural law. The Federal Circuit stated that claims were patent-eligible because they were “directed to a specific method of treatment for specific patients using a specific compound at specific doses to achieve specific outcome.”[3]  The United States Patent and Trade Mark Office (USPTO) issued a memorandum[4]  based on the Federal Circuit’s Vanda decision.

    By taking into account the Vanda decision and USPTO’s 2018 guidance, applicants can increase their chances for the successful prosecution of method-of-treatment claims that rely on an underlying natural law. For successful prosecution of such claims, applicants are reminded that:

    • The method should include concrete steps based on the information from the diagnosis step(s). A step of administering a treatment to obtain information but taking no concrete steps based on that information is not sufficient.
    • Every selected group of patients included in the claim should affirmatively receive a treatment. In other words, if treatment is to be withheld from a selected group, such a group should not be included in the claims.
    • The treatment should be capable of treating the disease or medical condition. Administering a treatment that is not known in the art to treat the disease or medical condition is not sufficient.
    • The treatment limitation should be specific. A step of administering a dosage different (e.g., lower or higher) than the normal dosage is specific; however, a step of simply “administering a suitable medication” is not specific.

    It remains to be seen if Congress will step up and clarify the uncertainty created by the Alice/Mayo framework. Until then, we are left with the Federal Circuit’s interpretation, which can be confusingly contradictory at times.


    1. See Mayo Collaborative Servs. V. Prometheus Labs., Inc., 566 U.S. 66 (2012) and the subsequent subject matter eligibility determination framework articulated in Alice Corp. v. CLS Bank International, 573 U.S. 2008 (2014).
      [Back to reference]
    2. Vanda Pharmaceuticals Inc. v. West-Ward Pharmaceuticals, 887 F.3d 1117 (Fed. Cir. 2018), cert. denied, No. 18-817 (Jan. 13, 2020).
      [Back to reference]
    3. Id. at 1136.
      [Back to reference]
    4. USPTO Memorandum of June 7, 2018, “Recent Subject Matter Eligibility Decision: Vanda Pharmaceuticals Inc. v. West-Ward Pharmaceuticals.”
      [Back to reference]

    Practices

    Intellectual Property

    Insights And Happenings

    • Alert

      Public opinion on patent eligibility law — far from a consensus

      Oct 26, 2021
    • Press Release

      IAM Patent 1000 recognizes Nixon Peabody and several of its IP attorneys as leaders in their field

      July 8, 2020
    • Alert

      Protect your heart: Purely diagnostic heart monitoring device found to be patent eligible subject matter

      May 7, 2020

    Subscribe to stay informed of the latest legal news, alerts, and business trends.Subscribe

    • People
    • Capabilities
    • Insights
    • About
    • Locations
    • Events
    • Careers
    • Alumni
    • © 2023 Nixon Peabody. All rights reserved
    • Privacy Policy
    • Terms of Use
    • Statement of Client Rights
    • Supplier Diversity Program
    • Nixon Peabody International LLC
    • PAL